PoteligeoActive Ingredient(s): Mogamulizumab-kpkc
FDA Approved: * August 8, 2018
Pharm Company: * KYOWA KIRIN
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refracto... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.